XTX Topco Ltd Purchases 3,851 Shares of Twist Bioscience Co. (NASDAQ:TWST)

XTX Topco Ltd boosted its position in shares of Twist Bioscience Co. (NASDAQ:TWST) by 51.4% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 11,349 shares of the company’s stock after acquiring an additional 3,851 shares during the period. XTX Topco Ltd’s holdings in Twist Bioscience were worth $559,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Artisan Partners Limited Partnership raised its position in shares of Twist Bioscience by 111.3% during the fourth quarter. Artisan Partners Limited Partnership now owns 3,723,305 shares of the company’s stock valued at $137,241,000 after buying an additional 1,961,621 shares during the last quarter. Victory Capital Management Inc. raised its position in shares of Twist Bioscience by 4,133.1% during the second quarter. Victory Capital Management Inc. now owns 308,171 shares of the company’s stock valued at $15,187,000 after buying an additional 300,891 shares during the last quarter. Norges Bank bought a new stake in shares of Twist Bioscience during the fourth quarter valued at approximately $10,766,000. Dimensional Fund Advisors LP raised its position in shares of Twist Bioscience by 29.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,267,708 shares of the company’s stock valued at $46,732,000 after buying an additional 284,884 shares during the last quarter. Finally, Baillie Gifford & Co. raised its position in shares of Twist Bioscience by 12.1% during the first quarter. Baillie Gifford & Co. now owns 1,227,528 shares of the company’s stock valued at $42,116,000 after buying an additional 132,770 shares during the last quarter.

Insider Activity at Twist Bioscience

In other Twist Bioscience news, CEO Emily M. Leproust sold 1,114 shares of the company’s stock in a transaction that occurred on Tuesday, July 2nd. The stock was sold at an average price of $48.00, for a total value of $53,472.00. Following the sale, the chief executive officer now owns 504,732 shares in the company, valued at approximately $24,227,136. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, COO Patrick John Finn sold 2,207 shares of the stock in a transaction on Tuesday, July 23rd. The stock was sold at an average price of $56.62, for a total value of $124,960.34. Following the completion of the transaction, the chief operating officer now directly owns 171,212 shares of the company’s stock, valued at approximately $9,694,023.44. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Emily M. Leproust sold 1,114 shares of the stock in a transaction on Tuesday, July 2nd. The shares were sold at an average price of $48.00, for a total value of $53,472.00. Following the completion of the transaction, the chief executive officer now directly owns 504,732 shares of the company’s stock, valued at $24,227,136. The disclosure for this sale can be found here. Insiders have sold a total of 15,125 shares of company stock worth $664,784 over the last quarter. Insiders own 3.92% of the company’s stock.

Twist Bioscience Trading Down 2.5 %

Shares of TWST opened at $45.29 on Tuesday. The firm has a market capitalization of $2.64 billion, a P/E ratio of -13.48 and a beta of 1.76. Twist Bioscience Co. has a 12-month low of $14.42 and a 12-month high of $60.90. The firm has a fifty day moving average price of $47.05 and a 200-day moving average price of $43.14.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Friday, August 2nd. The company reported ($1.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.71). The firm had revenue of $81.50 million during the quarter, compared to the consensus estimate of $77.40 million. Twist Bioscience had a negative return on equity of 32.17% and a negative net margin of 74.63%. The business’s revenue for the quarter was up 27.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.01) earnings per share. Analysts predict that Twist Bioscience Co. will post -3.13 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Barclays cut their target price on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a report on Monday, August 5th. Robert W. Baird raised their target price on shares of Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a report on Monday, August 5th. Guggenheim assumed coverage on shares of Twist Bioscience in a report on Tuesday, June 4th. They issued a “buy” rating and a $53.00 target price for the company. The Goldman Sachs Group raised their target price on shares of Twist Bioscience from $45.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday, July 9th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research note on Monday, August 5th. One investment analyst has rated the stock with a sell rating and eight have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $48.22.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.